Johnson and Johnson (JNJ) has reported robust financial results for the second quarter of 2025, with sales rising 5.8 percent year-over-year to USD 23.7 billion, up from USD 22,447 billion in the same period last year. The company posted operational growth of 4.6 percent and adjusted operational growth of 3.0 percent for the quarter.    

Net earnings surged 18.2 percent to USD 5.54 billion, compared to USD 4.69 billion in Q2 2024, while earnings per share (EPS) stood at USD 2.29, with adjusted EPS at USD 2.77.  

“Today’s strong results reflect the depth and strength of Johnson and Johnson’s uniquely diversified business operating across both MedTech and Innovative Medicine,” said Joaquin Duato, Chairman and Chief Executive Officer of Johnson and Johnson.

“Our portfolio and pipeline position us for elevated growth in the second half of the year, with game-changing approvals and submissions anticipated in areas like lung and bladder cancer, major depressive disorder, psoriasis, surgery and cardiovascular, which will extend and improve lives in transformative ways,” he added.

The company reported significant progress across its research and development pipeline, including FDA approval of IMAAVY for generalized myasthenia gravis, priority review granted to TAR-200 in bladder cancer, positive data for CARVYKTI showing survival and progression-free benefits in multiple myeloma, and continuation of the clinical trial for a general surgery robotic system, OTTAVA.

Thanks to strong operational performance and favorable foreign exchange, the company has raised full-year reported sales growth guidance to 5.4 percent, increasing midpoint estimates by USD 2 billion, boosted full-year EPS guidance by USD 0.25 to USD 10.85 and adjusted operational EPS midpoint increased to USD 10.68.

Johnson and Johnson reported 3.8 percent growth in innovative medicine worldwide operational sales, with a 1.4 percent boost from net acquisitions and divestitures.

“Growth was primarily driven by DARZALEX, CARVYKTI, ERLEADA and RYBREVANT/LAZCLUZE in oncology, TREMFYA and SIMPONI/SIMPONI ARIA in immunology, and SPRAVATO in neuroscience,” the company stated.  

In MedTech, its worldwide operational sales increased 6.1 percent, positively impacted by 2.0 percent from acquisitions and divestitures. Key drivers included electrophysiology products and Abiomed in cardiovascular, as well as wound closure products in general surgery.

In a separate announcement, the company’s Board of Directors declared a cash dividend of USD 1.30 per share for the third quarter of 2025 on its common stock. The dividend is payable on September 9, 2025, to shareholders of record as of the close of business on August 26, 2025. The ex-dividend date is also August 26, 2025.